AD26.RSV.PREF clinical trials
Also written JNJ-64400141.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses AD26.RSV.PREF is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
RSV pref protein (1)
Studies
Open first, then newest update. How each study uses AD26.RSV.PREF is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of AgeCompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT03303625Written as Ad26.RSV.preF (1*10^11 vp)
- A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and OlderCompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT03502707Written as Ad26.RSV.preF 1*10^11 vp
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of AgeCompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT03606512Written as Ad26.RSV.preF
- An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old AdultsCompletedPhase 2Janssen Vaccines & Prevention B.V.NCT03334695Written as Ad26.RSV.preF
- A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable HealthCompletedPhase 2Janssen Vaccines & Prevention B.V.NCT03339713Written as Ad26.RSV.preF
- A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in AdultsCompletedPhase 1Janssen Vaccines & Prevention B.V.NCT03795441Written as Ad26.RSV.preF
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable HealthCompletedPhase 1Janssen Vaccines & Prevention B.V.NCT02926430Written as Ad26.RSV.preF 5*10^10 vp